Trial Profile
Maintenance Brentuximab Vedotin (Bv) Following Allogeneic Stem Cell Transplantation for Hodgkin Lymphoma Patient: A Prospective, Multicenter, Phase II Study Maintenance Brentuximab Vedotin (Bv) Following Allogeneic Stem Cell Transplantation for Hodgkin Lymphoma Patient: A Prospective, Multicenter, Phase II Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2023
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms BVALLO
- 10 Mar 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified May 2018).
- 12 Oct 2020 This trial has been Discontinued (Global End Date: 23 Jul 2020), according to European Clinical Trials Database record.
- 25 Jan 2018 New trial record